OncoSec Medical Inc Beta
Was ist das Beta von OncoSec Medical Inc?
Beta von OncoSec Medical Inc ist 0.00
Was ist die Definition von Beta?
BETA gibt an, ob eine Aktie mehr oder weniger schwankungsanfällig ist als der Gesamtmarkt. Ein Beta von weniger als 1 zeigt an, dass die Aktie weniger schwankungsanfällig ist als der Markt, während ein Beta von mehr als 1 anzeigt, dass die Aktie mehr schwankungsanfällig ist. Die Schwankungsanfälligkeit wird als Schwankung des Preises um den Mittelwert gemessen.
Beta is a measure of the risk arising from exposure to general market movements as opposed to idiosyncratic factors. The market portfolio of all investable assets has a beta of exactly 1. A beta below 1 can indicate either an investment with lower volatility than the market, or a volatile investment whose price movements are not highly correlated with the market. A beta greater than one generally means that the asset both is volatile and tends to move up and down with the market. Beta is important because it measures the risk of an investment that cannot be reduced by diversification. It does not measure the risk of an investment held on a stand-alone basis, but the amount of risk the investment adds to an already-diversified portfolio. In the capital asset pricing model, beta risk is the only kind of risk for which investors should receive an expected return higher than the risk-free rate of interest.
Beta von Unternehmen in Health Care Sektor auf NASDAQ im Vergleich zu OncoSec Medical Inc
Was macht OncoSec Medical Inc?
oncosec is a san diego-based biotechnology company pioneering new technologies to stimulate the body’s immune system to target and attack cancer. through our proprietary technology, we hope to deliver safer and more effective cancer treatments that can provide long-term benefits for patients. our technology, immunopulse™, is designed to enhance the local delivery and uptake of dna-based immune-targeting agents, such as il-12. clinical trials of immunopulse™ il-12 demonstrated a favorable safety profile and evidence of anti-tumor activity in the treatment of various skin cancers as well as the potential to initiate a systemic immune response. our lead program, immunopulse™ il-12, is currently in phase ii development for several indications, including metastatic melanoma, squamous cell carcinoma of the head and neck, and triple-negative breast cancer. to date, study results have laid the groundwork for the expansion into new dna-encoded therapeutic candidates and tumor indications. we ar
Unternehmen mit beta ähnlich OncoSec Medical Inc
- Vision Marine Technologies hat Beta von 0.00
- Ely Gold Royalties hat Beta von 0.00
- Glacier Lake Resources hat Beta von 0.00
- Magnum Mining and Exploration hat Beta von 0.00
- Africa Opportunity Fund hat Beta von 0.00
- Fulcrum Utility Services hat Beta von 0.00
- OncoSec Medical Inc hat Beta von 0.00
- Gullewa hat Beta von 0.00
- S.A.L. Steel hat Beta von 0.00
- Andina Acquisition III hat Beta von 0.00
- Andina Acquisition III hat Beta von 0.00
- Brilliant Acquisition hat Beta von 0.00
- Indokem hat Beta von 0.00